Overview
- The company sold about 10.3 million shares at $17 each to raise $175 million in a U.S. initial public offering that priced within its marketed range.
- Windward began trading on Nasdaq under the ticker WWB on Friday, Nov. 13, with shares opening at $18.35 and the company reporting a first-day close of $28.50.
- Windward’s lead drug candidate, WIN378, is an anti‑TSLP antibody engineered to reduce airway inflammation in asthma and COPD and is currently in mid‑stage clinical testing.
- Before going public the company had raised roughly $310 million from investors including Novo Holdings, OrbiMed, Blue Owl and RTW, and Sanofi committed $50 million in a related private placement.
- Led by serial founder Luca Santarelli, Windward enters public markets at a time when biotech listings have picked up and the company will use the proceeds to fund ongoing clinical development and trials.